{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-000738","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.968665+00:00","generated_at":"2026-06-20T17:39:44.823478+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Esperion prelim Q4 2022 US revenue $14.4-15.1M (+38-40% YoY); CLEAR Outcomes submissions planned 1H 2023","bullets":["Preliminary Q4 2022 U.S. net product revenue $14.4M-$15.1M; full-year 2022 growth 38%-40% YoY.","Cash and investment securities ~$167M as of Dec 31, 2022; ~74.6M shares outstanding.","Plans to submit CLEAR Outcomes data to FDA and EMA in 1H 2023; expects partner milestone payments upon approvals.","Announces 12-month marketing partnership with RFK Racing to boost brand awareness among 10M+ fans.","Presenting at J.P. Morgan 41st Annual Healthcare Conference."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-000738","json":"https://secwatch.observer/filing/0001628280-23-000738.json","markdown":"https://secwatch.observer/filing/0001628280-23-000738.md","text":"https://secwatch.observer/filing/0001628280-23-000738.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000162828023000738/0001628280-23-000738-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000162828023000738/espr-20230108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:39:44.823478+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b6c717bd30b80e4cace42c039a49fdd20701e7dd","claim":"Esperion Therapeutics, Inc. reported fourth-quarter 2022 results: revenue $14.4 to $15.1 million.","evidence_excerpt":"Preliminary, unaudited fourth-quarter 2022 net U.S. product sales are expected to be between $14.4 to $15.1 million; FY growth between 38% and 40% year over year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828023000738/0001628280-23-000738-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth-quarter 2022"},{"label":"Revenue","value":"$14.4 to $15.1 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}